ClinicalTrials.gg
RecruitingNCT06222645Updated Nov 18, 2025

PPG vs. ICG in Gastrointestinal Resections

An interventional study of ICG fluorescence imaging technology and Imaging Photoplethysmography System in Anastomosis, Perfusion and Postoperative Complications, sponsored by Saint Petersburg State University, Russia. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Saint Petersburg State University, Russia · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This randomized controlled trial compares a novel optical technique against the standard of care for assessing tissue perfusion in gastrointestinal surgery. Participants are randomized to receive either intraoperative imaging photoplethysmography (iPPG) or indocyanine green (ICG) fluorescence imaging. In the ICG group, the fluorescence data are comprehensively analyzed in two distinct ways: (1) Qualitative Assessment: real-time visual interpretation of the angiogram flow by the operating surgeon; and (2) Quantitative Assessment: software-based analysis of fluorescence kinetics (e.g., time-to-peak, maximum intensity) to generate objective perfusion parameters. The study aims to determine the agreement between the iPPG-based evaluations and both the qualitative and quantitative dimensions of the ICG standard.

Read the detailed description

This randomized, parallel-group clinical study aims to compare two intraoperative imaging strategies for assessing tissue perfusion in a spectrum of gastrointestinal anastomoses, including both gastro-intestinal and entero-enteric reconstructions. The primary objective is to evaluate the diagnostic performance and clinical utility of a novel, non-contact optical technique-imaging photoplethysmography (iPPG)-against the current clinical standard, indocyanine green (ICG) fluorescence imaging.

Eligible and consented patients will be randomly assigned to one of two arms. The iPPG Arm will undergo perfusion evaluation solely using the investigational iPPG system. This method leverages a conventional video camera to detect pulsatile blood volume changes in microvascular tissue, offering a non-invasive, contrast-agent-free approach to perfusion assessment. The ICG Arm will be assessed using the standard fluorescence imaging protocol. A key feature of the study design is the pre-specified, comprehensive analysis within the ICG arm, which will incorporate both a qualitative assessment (the surgeon's real-time visual interpretation of the angiogram) and a quantitative analysis (computer-based calculation of fluorescence kinetics parameters, such as time-to-peak and inflow slope).

The study is designed to provide a head-to-head comparison of the two guiding strategies. Outcomes from the iPPG-guided arm will be systematically benchmarked against those from the ICG-guided arm. Furthermore, the internal comparison between qualitative and quantitative assessments within the ICG arm will yield valuable insights into the optimal methodology for interpreting perfusion data in clinical practice. This design allows for the evaluation of iPPG not only as a potential alternative to ICG but also for the refinement of the standard itself.

02

Conditions studied

  • Anastomosis
  • Perfusion
  • Postoperative Complications
  • Gastrointestinal Neoplasms
  • Gastric Cancer (GC)
  • Colorectal Cancer

Keywords

  • Photoplethysmography
  • Indocyanine Green
  • Fluorescence Imaging
  • Anastomotic Leak
  • Gastrointestinal Surgery
  • Tissue Perfusion
  • Intraoperative Monitoring
03

In context

Postoperative Complications

1,343 studies on the registry are indexed under Postoperative Complications; 314 are open to participants now.

This study's planned enrollment of 200 is above the median of 113 across 773 interventional studies indexed under Postoperative Complications.

Browse Postoperative Complications studies →

Lead sponsor

Saint Petersburg State University, Russia is the lead sponsor of 34 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (age ≥ 18 years).
  • Scheduled to undergo an elective gastrointestinal resection requiring a primary gastro-intestinal or entero-enteric anastomosis.
  • Able to understand and provide written .

Exclusion criteria

Exclusion Criteria:

  • Known or allergy to indocyanine green (ICG), iodine, or any component of the ICG formulation.
  • Severe hepatic impairment (e.g., Class C).
  • Pregnancy or lactation.
  • Emergency surgery.
  • Inability to comply with the study protocol or follow-up schedule in the investigator's judgment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Indocyanine green (ICG) imaging system

    Participants in this arm undergo intraoperative tissue perfusion assessment guided by the standard Indocyanine Green (ICG) fluorescence imaging. This involves intravenous ICG injection. Perfusion is evaluated comprehensively through both qualitative (surgeon's visual interpretation) and quantitative (computer-based analysis of fluorescence kinetics, e.g., time-to-peak) methods. This arm represents the current standard of care.

    Drug: ICG fluorescence imaging technology · Device: Imaging Photoplethysmography System

  • Experimental
    imaging photoplethysmography (iPPG)

    Participants in this arm undergo intraoperative tissue perfusion assessment guided by the investigational Imaging Photoplethysmography (iPPG) system. This non-contact, camera-based technique detects microvascular blood volume changes without requiring exogenous contrast agents. The surgical team uses the real-time iPPG perfusion maps to evaluate anastomotic viability and guide surgical decisions.

    Drug: ICG fluorescence imaging technology · Device: Imaging Photoplethysmography System

Interventions

  • DrugICG fluorescence imaging technology

    This intervention involves the intravenous injection of the fluorescent contrast agent Indocyanine Green (ICG), followed by imaging with a near-infrared fluorescence camera system. Upon illumination with near-infrared light, ICG in the bloodstream fluoresces, allowing for real-time visualization of blood flow and tissue perfusion (qualitative assessment). Additionally, the fluorescence intensity over time can be recorded for subsequent quantitative analysis of perfusion kinetics.

    Also known as: ICG Imaging, ICG Angiography, Near-Infrared Fluorescence Imaging

  • DeviceImaging Photoplethysmography System

    Imaging photoplethysmography is a non-contact, camera-based optical imaging technique. This investigational system operates by detecting subtle modulations in optical signals associated with pulsatile blood volume changes in microvascular tissue. It utilizes a conventional video camera to capture these signals and generates real-time tissue perfusion maps without the need for any exogenous contrast agents. The system is designed to provide intraoperative guidance for assessing tissue viability during gastrointestinal anastomoses.

    Also known as: iPPG, PPG Imaging

06

What researchers measure

Primary outcomes

  1. Incidence of Anastomotic Leak

    Comparison of the rate of clinically significant anastomotic leak between the iPPG-guided group and the ICG-guided group. Anastomotic leak is defined as a full-thickness defect requiring radiological, endoscopic, or surgical intervention, as confirmed by an independent clinical events committee within 30 days postoperatively.

    Time frame: 30 days postoperatively

  2. Incidence of Anastomotic Leak: Qualitative vs Quantitative ICG Assessment

    Comparison of the rate of clinically significant anastomotic leak between patients whose intraoperative assessment was based on qualitative ICG imaging (surgeon's visual interpretation) versus those assessed with quantitative ICG parameters (software-based kinetic analysis). Anastomotic leak is defined as a full-thickness gastrointestinal defect requiring postoperative radiological, endoscopic, or surgical intervention, as confirmed by an independent adjudication committee. This analysis will be performed specifically within the cohort of patients randomized to the ICG arm.

    Time frame: 30 days postoperatively

Secondary outcomes

  1. Diagnostic Performance for Predicting Anastomotic Leak

    To evaluate and compare the diagnostic accuracy of the intraoperative iPPG assessment versus the standard ICG assessment (including both qualitative and quantitative methods) in predicting the occurrence of a postoperative anastomotic leak. The perfusion assessment during surgery will be dichotomized as 'inadequate' or 'adequate'. Diagnostic performance metrics including Sensitivity, Specificity, Positive Predictive Value (PPV), Negative Predictive Value (NPV), and the Area Under the Receiver Operating Characteristic Curve (AUC-ROC) will be calculated for each modality against the clinical outcome of anastomotic leak.

    Time frame: he perfusion assessment is performed intraoperatively. The outcome (anastomotic leak) is assessed at 30 days postoperatively.

  2. Rate of Anastomotic Revision Based on Perfusion Assessment

    To quantify and compare the immediate impact of perfusion assessment on surgical decision-making by recording the frequency at which the operating surgeon decides to revise the anastomosis (i.e., resect and re-anastomose the bowel segment) based solely on the intraoperative findings of either iPPG or ICG imaging. The revision rate will be calculated as the proportion of patients in each arm (iPPG and ICG) for whom the anastomosis was revised due to perceived inadequate perfusion.

    Time frame: Intraoperative (Measured immediately following the perfusion assessment of the initially constructed anastomosis)

  3. Overall Postoperative Complication Rate

    To comprehensively evaluate and compare the overall postoperative morbidity between the iPPG-guided group and the ICG-guided group. All complications occurring within 30 days after surgery will be recorded and graded according to the Clavien-Dindo classification system. This standardized system categorizes complications based on the level of intervention required for management, ranging from Grade I (any deviation from the normal postoperative course not requiring pharmacological/surgical intervention) to Grade V (death). The comparison will focus on the incidence of complications of Grade II and above.

    Time frame: 30 days postoperatively

  4. Rate of Re-intervention

    To compare the incidence of unplanned, procedure-related re-interventions between the iPPG-guided and ICG-guided groups. A re-intervention is defined as any subsequent surgical, endoscopic, or radiology-guided invasive procedure required to manage a complication related to the initial gastrointestinal resection and anastomosis (e.g., control of bleeding, drainage of an intra-abdominal collection, or repair of an anastomotic leak). Planned, staged procedures are excluded. The rate is calculated as the proportion of patients in each group undergoing at least one such re-intervention.

    Time frame: 30 days postoperatively

Other outcomes

  1. Surgeon Confidence Score

    To quantify the surgeon's confidence in the adequacy of the anastomotic perfusion following the intraoperative assessment. Immediately after evaluating the perfusion with the assigned modality (iPPG or ICG) and before abdominal closure, the primary surgeon will rate their confidence on an 11-point numerical rating scale, ranging from 0 (no confidence in anastomotic viability) to 10 (absolute confidence in anastomotic viability). The mean confidence scores will be compared between the two study arms.

    Time frame: Intraoperative (Assessed immediately after perfusion evaluation and before fascial closure)

  2. Time from Imaging to Decision

    To compare the workflow efficiency between the iPPG and ICG assessment modalities. This measure records the time elapsed from the moment a clear, interpretable perfusion image is first available on the display to the moment the surgeon verbally communicates the final decision regarding the anastomosis (e.g., "proceed as is," "revise anastomosis," "create stoma"). The time is recorded in seconds for each assessed anastomosis.

    Time frame: Intraoperative (Measured for each anastomosis assessment event)

07

Study locations

2 of 3 sites recruiting
  • Shandong Linglong Yingcheng Hospital
    Yantai, Shandong 265400, China
    Recruiting
  • High-Tech Clinic Beloostrov
    Saint Petersburg, Leningradskaya Oblast' 197729, Russia
    Active, not recruiting

    Not enrolling at this site.

  • Department of Faculty Surgery, Saint Petersburg State University
    Saint Petersburg, Leningradskaya Oblast' 199034, Russia
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Apr 2026, 29 months after the start.

Of 395 non-industry interventional studies with no phase under Postoperative Complications, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 44. This study's planned 29 months is above that.

Counting every sponsor, half of 399 studies reached it within 20 months; a quarter within 8 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2023
First posted
Jan 25, 2024
StartActual
Nov 1, 2023
Primary completionEst.
Apr 30, 2026
CompletionEst.
May 31, 2026
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06222645
Lead sponsor
Saint Petersburg State University, Russia
Collaborators
Shandong Linglong Yingcheng Hospital, High-Tech Clinic Beloostrov
Responsible party
Xuan Qiu (Principal Investigator, Saint Petersburg State University, Russia) — Principal investigator
First posted
Jan 25, 2024
Start date
Nov 1, 2023
Primary completion
Apr 30, 2026 (estimated)
Completion
May 31, 2026 (estimated)
Last update
Nov 18, 2025

Study contacts

Xuan - Qiu, MD
Contact
st122986@student.spbu.ru
79643411524
Victor A. Kashchenko, MD,PD
Contact
surg122@yandex.ru
79119289525

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion